Menu Search
Equities

Pediatrix Medical Group Inc

MD:NYQ

Pediatrix Medical Group Inc

Actions
Health CareHealth Care Providers
  • Price (USD)15.16
  • Today's Change0.41 / 2.78%
  • Shares traded216.17k
  • 1 Year change+72.67%
  • Beta1.5619
Data delayed at least 15 minutes, as of Nov 22 2024 17:48 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy2
Outperform0
Hold6
Sell0
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for Pediatrix Medical Group Inc have a median target of 15.50, with a high estimate of 18.00 and a low estimate of 13.00. The median estimate represents a 5.08% increase from the last price of 14.75.
High22.0%18.00
Med5.1%15.50
Low-11.9%13.00

Earnings history & estimates in USD

On Nov 01, 2024, Pediatrix Medical Group Inc reported 3rd quarter 2024 earnings of 0.44 per share. This result exceeded the 0.37 consensus of the 7 analysts covering the company and exceeded last year's 3rd quarter results by 37.50%.
The next earnings announcement is expected on Feb 18, 2025.
Average growth rate+15.48%
Pediatrix Medical Group Inc reported annual 2023 earnings of 1.26 per share on Feb 20, 2024.
Average growth rate-5.64%
More ▼

Revenue history & estimates in USD

MEDNAX, Inc. had 3rd quarter 2024 revenues of 511.16m. This bettered the 498.87m consensus of the 7 analysts covering the company. This was 4.10% above the prior year's 3rd quarter results.
Average growth rate+0.24%
MEDNAX, Inc. had revenues for the full year 2023 of 1.99bn. This was 1.15% above the prior year's results.
Average growth rate-9.02%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.